Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P.

Open source

DOI: 10.1111/bjh.19819
Published: 2024-11-06
Container: Br J Haematol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bjh.19819,
  title = {Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.},
  author = {Huguet F and  Guerci-Bresler A and  Roth-Guepin G and  Cayssials E and  Slama B and  Santagostino A and  Penot A and  Quittet P and  Cony-Makhoul P and  Saad A and  Bastie JN and  Hacini M and  Coiteux V and  Uzunov M and  Roy L and  Le Clech L and  Berger M and  Agneray AM and  Messas E and  Etienne G and  Turhan A and  Nicolini FE and  Rousselot P.},
  year = {2024},
  journal = {Br J Haematol},
  doi = {10.1111/bjh.19819},
  url = {https://doi.org/10.1111/bjh.19819}
}

RIS

TY  - JOUR
TI  - Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
AU  - Huguet F
AU  -  Guerci-Bresler A
AU  -  Roth-Guepin G
AU  -  Cayssials E
AU  -  Slama B
AU  -  Santagostino A
AU  -  Penot A
AU  -  Quittet P
AU  -  Cony-Makhoul P
AU  -  Saad A
AU  -  Bastie JN
AU  -  Hacini M
AU  -  Coiteux V
AU  -  Uzunov M
AU  -  Roy L
AU  -  Le Clech L
AU  -  Berger M
AU  -  Agneray AM
AU  -  Messas E
AU  -  Etienne G
AU  -  Turhan A
AU  -  Nicolini FE
AU  -  Rousselot P.
PY  - 2024
JO  - Br J Haematol
DO  - 10.1111/bjh.19819
UR  - https://doi.org/10.1111/bjh.19819
ER  -

APA

F, H., A, G., G, R., E, C., B, S., A, S., A, P., P, Q., P, C., A, S., JN, B., M, H., V, C., M, U., L, R., L, L. C., M, B., AM, A., E, M., G, E., A, T., FE, N., & P., R. (2024). Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.. Br J Haematol. https://doi.org/10.1111/bjh.19819

Source records

europe-pmc · retrieved 2026-09-25T04:06:27.015Z